FDA‑Approved Uses of Ivermectin in Humans
| Indication (FDA‑approved) | Typical dose (adult) | Comments |
|---------------------------|----------------------|----------|
| Strongyloides stercoralis (strongyloidiasis) | 200 µg/kg PO once | 1–2 days; repeat if necessary |
| Onchocerciasis (river blindness) | 200 µg/kg PO once | Often given monthly in endemic areas |
| Scabies (topical 1 % lotion) | 1 % lotion applied to skin | 2 weeks apart for treatment |
| Head lice (topical 10 % solution) | 10 % solution applied to scalp | Usually a single dose |
| Other parasitic infections | Varies | e.g., cutaneous larva migrans, some nematode infections |
- Form: Ivermectin is available only in prescription oral capsules (for systemic uses) and topical preparations (for scabies/lice).
- Approval: The drug has been FDA‑approved for the above indications since the 1980s–1990s.
- Safety: When used as directed, ivermectin is generally well tolerated. Common side‑effects include dizziness, nausea, and mild gastrointestinal upset. Serious adverse events are rare but can occur, especially at higher doses or in patients with pre‑existing liver disease.
What the FDA Has NOT Approved
| Claim | FDA Status |
|-------|------------|
| COVID‑19 treatment or prevention | Not approved; no FDA approval or EUA. The agency has repeatedly stated that there is insufficient evidence for efficacy and safety in this context. |
| “Off‑label” uses for other diseases | Unapproved; doctors can prescribe off‑label, but this is not endorsed or supported by robust clinical trials. |
| OTC availability | Prescription‑only. Ivermectin is not an over‑the‑counter drug in the United States. |
Why the Distinction Matters
- Regulatory Review: The FDA evaluates each indication separately. Approval for parasitic infections does not automatically confer approval for other conditions.
- Clinical Evidence: For COVID‑19 and other claims, the available studies have mixed results, many of which are low quality or not peer‑reviewed. The FDA requires large, well‑controlled randomized trials to demonstrate safety and benefit before granting approval.
- Safety Monitoring: The FDA tracks adverse events through VAERS and other reporting systems. Reports of serious side‑effects (e.g., neurological symptoms, liver injury) have been documented in a small minority of patients who receive doses outside the approved range.
Practical Take‑Away
1. Use Ivermectin only for its FDA‑approved indications—as prescribed by a licensed healthcare provider.
2. Do not self‑medicate with ivermectin, especially for unapproved uses like COVID‑19.
3. Consult a healthcare professional if you have questions about whether ivermectin might help with a specific condition.
Quick Reference
- Where to get it: Pharmacy (prescription).
- Who can prescribe: Doctors, nurse practitioners, physician assistants.
- What to ask: “Is ivermectin appropriate for my condition?” and “What dose and duration are needed?”
If you’re looking for information on a particular disease or symptom, let me know and I can give you more detailed guidance on whether ivermectin is appropriate and what alternative treatments might be available.